NEW DELHI: Even as Covid-19 has disrupted screening and treatment of tuberculosis derailing efforts to eliminate it, the BPaL regimen to reduce treatment time from 18 months to 6 months and reported success rate of 90% can be crucial in the fight against TB.
BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB Alliance developed antibiotic pretomanid, along with two other antibiotics: bedaquiline and linezolid. While the BPaL regimen was approved by the drug regulator in India last year, TB Alliance’s latest trial results show that the high efficacy of the BPaL regimen can be maintained with lower dosing of linezolid, which is associated with challenging side effects including peripheral neuropathy. This is expected to boost the use of the drug. “TB Alliance is encouraged by these results, which support the use of reduced linezolid dosing in the sixmonth, three-drug, all-oral BPaL regimen,”
India
Mel-spigelman
Tb-alliance
இந்தியா
டீபீ-கூட்டணி
BPaL regimen can cut time for treatment of drug-resistant TB
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
IndiaMel-spigelmanTb-allianceஇந்தியாடீபீ-கூட்டணி